Oryzon Genomics announces publication of phase 2a ALICE trial results
Betsy Goodfellow | June 4, 2024 | News story | Medical Communications | AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial
Oryzon Genomics has announced that the final results from its phase 2a ALICE study have been published online in The Lancet Hematology.
The trial evaluated iadademstat in combination with azacytidine in unfit patients with newly diagnosed acute myeloid leukaemia (AML). A summary of this final data was previously shared in an oral presentation at the 2022 American Society for Hematology (ASH) annual meeting.
The data showed that this combination induced 82% of patients having an objective response, and 52% of patients achieving either a complete remission (CR) or a complete remission with incomplete haematological recovery (CRi). Many of the responses (87%) occurred rapidly, with 36% lasting at least 12 months.
Dr Carlos Buesa, chief executive officer of Oryzon Genomics, commented: “We are thrilled to publish these groundbreaking results in one of the most prestigious journals in clinical oncology. Our study demonstrates that targeting LSD1 is a completely novel anti-leukaemic mechanism of action in AML, potentially offering a new therapeutic approach, especially for patients with hard-to-treat forms of the disease such as myelomonocytic leukaemias, DNMTs mutations or TP53 mutations. These patients currently respond poorly to available treatments and may benefit from the innovative treatment option of iadademstat. We want to reiterate our gratitude to the patients, their families and the researchers involved in this study.”
Betsy Goodfellow
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
